ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION.
On
The information contained in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.
ITEM 3.03. MATERIAL MODIFICATION TO RIGHTS OF SECURITY HOLDERS.
On
Subsequent upgrades to the Company's long-term senior, unsecured debt credit ratings may result in a further decrease in the interest rate on the 2035 Notes, but in no event will the interest rate payable on the 2035 Notes be adjusted below 6.25%.
A copy of the Second Supplemental Indenture and the related notice to holders of the 2035 Notes are attached hereto as Exhibit 4.1 and Exhibit 99.2, respectively, and are incorporated herein by reference. The foregoing description of the Second Supplemental Indenture is qualified in its entirety by reference to the full text of the Second Supplemental Indenture.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.
(d) Exhibits Exhibit No. Description
4.1 Second Supplemental Indenture dated as of
and
Company, National Association, as Trustee (incorporated herein by
reference to Exhibit 99.6, Current Report on Form 8-K dated
99.1 Press Release issued by Boston Scientific Corporation dated October 27, 2021 99.2 Not ice to Holders of Boston Scientific Corporation's 7.00% Senior Notes due 2035
104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL
document
--------------------------------------------------------------------------------
© Edgar Online, source